Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

KATHERINE B REED

Allopathic & Osteopathic Physicians Dermatology

NPI
1396919569
CMS profile
335358
Location
SPOKANE, WA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$547.33

32 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $547.33 32

By paying entity

PY2019 · entire year · sorted by reported total

Page 1 of 1; records 1–32 of 32 matching records. This page contains 32 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

KATHERINE B REED

NPI 1396919569 · CMS profile ID 335358

Allopathic & Osteopathic Physicians / Dermatology

SPOKANE, WA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–32 of 32 matching records. This page contains 32 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1396919569?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
KATHERINE B REED, NPI 1396919569, CMS profile ID 335358. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–32 of 32 matching records. This page contains 32 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1396919569?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). KATHERINE B REED, NPI 1396919569, CMS profile ID 335358. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–32 of 32 matching records. This page contains 32 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1396919569?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
KATHERINE B REED, NPI 1396919569, CMS profile ID 335358, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–32 of 32 matching records. This page contains 32 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1396919569?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

32 matching records · $547.33 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 32 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–32 of 32.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
GENZYME CORPORATION $15.0711/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694219337 CMS
Lilly USA, LLC $17.4011/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657930113 CMS
Novartis Pharmaceuticals Corporation $13.0710/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659860567 CMS
Biofrontera Inc. $7.7710/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 690544023 CMS
AbbVie, Inc. $18.9710/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647699319 CMS
Celgene Corporation $23.9408/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672886457 CMS
Amgen Inc. $12.1208/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662591459 CMS
Novartis Pharmaceuticals Corporation $17.5708/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659860565 CMS
Lilly USA, LLC $15.8708/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657943901 CMS
AbbVie, Inc. $21.3407/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647699313 CMS
Celgene Corporation $24.3607/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672886273 CMS
GENZYME CORPORATION $17.8707/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694098869 CMS
Lilly USA, LLC $18.1207/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657950651 CMS
PFIZER INC. $16.4606/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672253685 CMS
AbbVie, Inc. $17.9206/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647699331 CMS
Integra LifeSciences Corporation $25.3306/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697158539 CMS
AbbVie, Inc. $15.5206/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647699327 CMS
AbbVie, Inc. $17.0105/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647699311 CMS
Novartis Pharmaceuticals Corporation $12.2505/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659860563 CMS
PruGen, Inc. Pharmaceuticals $13.5605/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 707764987 CMS
PFIZER INC. $18.4505/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672021947 CMS
Lilly USA, LLC $14.2405/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657930111 CMS
AbbVie, Inc. $17.1304/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647699353 CMS
Amgen Inc. $13.2104/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662591457 CMS
Helsinn Therapeutics (U.S.), Inc. $15.7804/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 655947391 CMS
AbbVie, Inc. $15.0403/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647699325 CMS
Lilly USA, LLC $17.2003/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657950649 CMS
PFIZER INC. $20.0902/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671891609 CMS
Biofrontera Inc. $20.9702/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 667996653 CMS
PFIZER INC. $16.6502/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671853273 CMS
Lilly USA, LLC $19.9101/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657926571 CMS
AbbVie, Inc. $17.1401/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647699321 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $547.33 32
PY2020 $413.54 18
PY2021 $570.86 34
PY2022 $538.17 34
PY2023 $498.08 30
PY2024 $705.53 35
PY2025 $1,169.72 67

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $734,267.33 246
PY2024 Principal investigator $853,745.12 356
PY2023 Principal investigator $644,757.85 253
PY2022 Principal investigator $361,336.03 142
PY2021 Principal investigator $277,998.71 117
PY2020 Principal investigator $149,365.00 24
PY2019 Principal investigator $53,682.69 24

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

356 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $19,147.80 12/30/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1100763468
Principal investigator 1 ABBVIE INC. $530.64 12/26/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1100762702
Principal investigator 1 Incyte Corporation $1,364.00 12/13/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690873
Principal investigator 1 Incyte Corporation $1,068.00 12/11/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
An Open-Label, Single-Arm, Phase 4 Study of Ruxolitinib Cream in Adults With Atopic Dermatitis Experiencing Sleep Disturbance in the United States (MORPHEUS) No dispute reported 06/30/2026 1134690633
Principal investigator 1 Incyte Corporation $2,312.02 12/11/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
An Open-Label, Single-Arm, Phase 4 Study of Ruxolitinib Cream in Adults With Atopic Dermatitis Experiencing Sleep Disturbance in the United States (MORPHEUS) No dispute reported 06/30/2026 1134690641
Principal investigator 1 ABBVIE INC. $26,846.10 12/05/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1100759659
Principal investigator 1 Eli Lilly and Company $23,939.41 12/05/2024 Non-covered Recipient Entity
BIOCLINICA INC
A PHASE 1/2 ASCENDING DOSE STUDY TO EVALUATE THE SAFETY AND EFFECTS ON PROGRANULIN LEVELS OF LY3884963 IN PATIENTS WITH FRONTO-TEMPORAL DEMENTIA WITH PROGRANULIN MUTATIONS (FTD-GRN) No dispute reported 06/30/2026 1137354796
Principal investigator 1 Incyte Corporation $54.80 12/02/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690527
Principal investigator 1 Incyte Corporation $54.80 12/02/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690529
Principal investigator 1 Incyte Corporation $7.20 12/02/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690885
Principal investigator 1 Incyte Corporation $16.20 12/02/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690887
Principal investigator 1 Incyte Corporation $118.30 12/02/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690889
Principal investigator 1 Incyte Corporation $57.30 12/02/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690891
Principal investigator 1 Incyte Corporation $48.50 12/02/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690893
Principal investigator 1 Incyte Corporation $49.40 12/02/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690895
Principal investigator 1 Incyte Corporation $103.00 12/02/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690903
Principal investigator 1 ABBVIE INC. $1,515.80 11/27/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3 Multicenter, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lutikizumab in Adult and Adolescent Subjects With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1100756737
Principal investigator 1 Incyte Corporation $1,479.00 11/20/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690875
Principal investigator 1 Incyte Corporation $948.90 11/20/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690955
Principal investigator 1 Incyte Corporation $1,371.00 11/20/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690959
Principal investigator 1 ABBVIE INC. $1,540.00 11/15/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3 Multicenter, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lutikizumab in Adult and Adolescent Subjects With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1100755553
Principal investigator 1 ABBVIE INC. $10,040.00 11/15/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3 Multicenter, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lutikizumab in Adult and Adolescent Subjects With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1100755555
Principal investigator 1 ABBVIE INC. $6,764.90 11/15/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3 Multicenter, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lutikizumab in Adult and Adolescent Subjects With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1100755557
Principal investigator 1 ABBVIE INC. $994.50 11/15/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3 Multicenter, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lutikizumab in Adult and Adolescent Subjects With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1100755559
Principal investigator 1 ABBVIE INC. $186.94 11/15/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3 Multicenter, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lutikizumab in Adult and Adolescent Subjects With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1100755561
Principal investigator 1 Incyte Corporation $1,832.00 11/14/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
An Open-Label, Single-Arm, Phase 4 Study of Ruxolitinib Cream in Adults With Atopic Dermatitis Experiencing Sleep Disturbance in the United States (MORPHEUS) No dispute reported 06/30/2026 1134690631
Principal investigator 1 Incyte Corporation $3,566.00 11/08/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690861
Principal investigator 1 Arcutis Biotherapeutics, Inc. $1,700.00 10/28/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.15% and ARQ-151 Cream 0.05% in Subjects with Atopic Dermatitis No dispute reported 06/30/2026 1121031210
Principal investigator 1 Incyte Corporation $2,094.00 10/18/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690867
Principal investigator 1 Incyte Corporation $1,479.00 10/18/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690869
Principal investigator 1 Incyte Corporation $876.60 10/18/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690871
Principal investigator 1 Incyte Corporation $2,671.00 10/16/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690863
Principal investigator 1 Incyte Corporation $600.00 10/16/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690865
Principal investigator 1 Incyte Corporation $1,000.00 10/16/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690951
Principal investigator 1 Incyte Corporation $30.00 10/11/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690859
Principal investigator 1 Incyte Corporation $84.00 10/11/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690917
Principal investigator 1 Incyte Corporation $750.00 10/10/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
An Open-Label, Single-Arm, Phase 4 Study of Ruxolitinib Cream in Adults With Atopic Dermatitis Experiencing Sleep Disturbance in the United States (MORPHEUS) No dispute reported 06/30/2026 1134690639
Principal investigator 1 Incyte Corporation $10,000.00 10/09/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1134690621
Principal investigator 1 Incyte Corporation $894.40 10/09/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
An Open-Label, Single-Arm, Phase 4 Study of Ruxolitinib Cream in Adults With Atopic Dermatitis Experiencing Sleep Disturbance in the United States (MORPHEUS) No dispute reported 06/30/2026 1134690637
Principal investigator 1 Incyte Corporation $905.26 10/09/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
An Open-Label, Single-Arm, Phase 4 Study of Ruxolitinib Cream in Adults With Atopic Dermatitis Experiencing Sleep Disturbance in the United States (MORPHEUS) No dispute reported 06/30/2026 1134690643
Principal investigator 1 Incyte Corporation $80.20 10/02/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690877
Principal investigator 1 Incyte Corporation $186.80 10/02/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690879
Principal investigator 1 Incyte Corporation $135.40 10/02/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690881
Principal investigator 1 Incyte Corporation $62.30 10/02/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690883
Principal investigator 1 Arcutis Biotherapeutics, Inc. $800.00 10/01/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.15% and ARQ-151 Cream 0.05% in Subjects with Atopic Dermatitis No dispute reported 06/30/2026 1121031212
Principal investigator 1 Arcutis Biotherapeutics, Inc. $8,724.80 10/01/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.15% and ARQ-151 Cream 0.05% in Subjects with Atopic Dermatitis No dispute reported 06/30/2026 1121031214
Principal investigator 1 Incyte Corporation $450.00 09/27/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690857
Principal investigator 1 Incyte Corporation $1,479.00 09/20/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690441
Principal investigator 1 Incyte Corporation $1,479.00 09/20/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690455
Principal investigator 1 Incyte Corporation $2,094.00 09/20/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690841
Principal investigator 1 Incyte Corporation $361.00 09/20/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690845
Principal investigator 1 Incyte Corporation $555.50 09/20/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690853
Principal investigator 1 Incyte Corporation $1,371.00 09/20/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690897
Principal investigator 1 Incyte Corporation $4.72 09/19/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
An Open-Label, Single-Arm, Phase 4 Study of Ruxolitinib Cream in Adults With Atopic Dermatitis Experiencing Sleep Disturbance in the United States (MORPHEUS) No dispute reported 06/30/2026 1134690645
Principal investigator 1 Incyte Corporation $130.00 09/18/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690431
Principal investigator 1 Incyte Corporation $1,942.00 09/18/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690439
Principal investigator 1 Incyte Corporation $1,942.00 09/18/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690453
Principal investigator 1 Incyte Corporation $130.00 09/18/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690465
Principal investigator 1 Incyte Corporation $1,364.00 09/18/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690927
Principal investigator 1 Incyte Corporation $2,406.30 09/05/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
An Open-Label, Single-Arm, Phase 4 Study of Ruxolitinib Cream in Adults With Atopic Dermatitis Experiencing Sleep Disturbance in the United States (MORPHEUS) No dispute reported 06/30/2026 1134690635
Principal investigator 1 Incyte Corporation $6.18 09/04/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690823
Principal investigator 1 Incyte Corporation $118.26 09/04/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690847
Principal investigator 1 Incyte Corporation $4.86 09/04/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690849
Principal investigator 1 Incyte Corporation $1,371.00 08/27/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690313
Principal investigator 1 Incyte Corporation $1,371.00 08/27/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690437
Principal investigator 1 Incyte Corporation $1,479.00 08/27/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690443
Principal investigator 1 Incyte Corporation $1,479.00 08/27/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690445
Principal investigator 1 Incyte Corporation $1,371.00 08/27/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690447
Principal investigator 1 Incyte Corporation $1,479.00 08/27/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690449
Principal investigator 1 Incyte Corporation $1,371.00 08/27/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690451
Principal investigator 1 Incyte Corporation $1,479.00 08/27/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690457
Principal investigator 1 Incyte Corporation $1,479.00 08/27/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690459
Principal investigator 1 Incyte Corporation $1,371.00 08/27/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690461
Principal investigator 1 Incyte Corporation $1,371.00 08/27/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690467
Principal investigator 1 Incyte Corporation $361.00 08/27/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690491
Principal investigator 1 Incyte Corporation $361.00 08/27/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690493
Principal investigator 1 Incyte Corporation $361.00 08/27/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690495
Principal investigator 1 Incyte Corporation $361.00 08/27/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690497
Principal investigator 1 Incyte Corporation $361.00 08/27/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690499
Principal investigator 1 Incyte Corporation $361.00 08/27/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690501
Principal investigator 1 Incyte Corporation $1,479.00 08/27/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690515
Principal investigator 1 Incyte Corporation $1,479.00 08/27/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690517
Principal investigator 1 Incyte Corporation $1,479.00 08/27/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690519
Principal investigator 1 Incyte Corporation $1,371.00 08/27/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690569
Principal investigator 1 Incyte Corporation $302.70 08/27/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690855
Principal investigator 1 Incyte Corporation $982.92 08/22/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
An Open-Label, Single-Arm, Phase 4 Study of Ruxolitinib Cream in Adults With Atopic Dermatitis Experiencing Sleep Disturbance in the United States (MORPHEUS) No dispute reported 06/30/2026 1134690793
Principal investigator 1 Incyte Corporation $1,942.00 08/14/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690433
Principal investigator 1 Incyte Corporation $1,334.00 08/14/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690435
Principal investigator 1 Incyte Corporation $1,942.00 08/14/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690463
Principal investigator 1 Incyte Corporation $1,334.00 08/14/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690615
Principal investigator 1 Incyte Corporation $1,364.00 08/14/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690839
Principal investigator 1 Incyte Corporation $510.00 08/12/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690629
Principal investigator 1 Incyte Corporation $130.00 08/12/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690827
Principal investigator 1 Incyte Corporation $516.00 08/12/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690837
Principal investigator 1 Incyte Corporation $546.00 08/12/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690907
Principal investigator 1 Incyte Corporation $1,229.58 08/07/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
An Open-Label, Single-Arm, Phase 4 Study of Ruxolitinib Cream in Adults With Atopic Dermatitis Experiencing Sleep Disturbance in the United States (MORPHEUS) No dispute reported 06/30/2026 1134690801
Principal investigator 1 Incyte Corporation $1,312.35 08/07/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
An Open-Label, Single-Arm, Phase 4 Study of Ruxolitinib Cream in Adults With Atopic Dermatitis Experiencing Sleep Disturbance in the United States (MORPHEUS) No dispute reported 06/30/2026 1134690805
Principal investigator 1 Incyte Corporation $22.90 08/01/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690619
Principal investigator 1 Incyte Corporation $68.70 08/01/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690821
Principal investigator 1 Incyte Corporation $24.30 08/01/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690851
Principal investigator 1 Incyte Corporation $54.76 08/01/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690899
Principal investigator 1 Incyte Corporation $130.00 07/26/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690825
Principal investigator 1 Incyte Corporation $102.24 07/25/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
An Open-Label, Single-Arm, Phase 4 Study of Ruxolitinib Cream in Adults With Atopic Dermatitis Experiencing Sleep Disturbance in the United States (MORPHEUS) No dispute reported 06/30/2026 1134690795
Principal investigator 1 Incyte Corporation $130.00 07/24/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690831
Principal investigator 1 Incyte Corporation $11,829.00 07/24/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690835
Principal investigator 1 Incyte Corporation $1,500.00 07/18/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) No dispute reported 06/30/2026 1134690791
Principal investigator 1 Incyte Corporation $58.00 07/18/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
An Open-Label, Single-Arm, Phase 4 Study of Ruxolitinib Cream in Adults With Atopic Dermatitis Experiencing Sleep Disturbance in the United States (MORPHEUS) No dispute reported 06/30/2026 1134690797
Principal investigator 1 Incyte Corporation $130.00 07/17/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690429
Principal investigator 1 Incyte Corporation $130.00 07/17/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690469
Principal investigator 1 Incyte Corporation $130.00 07/17/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690471
Principal investigator 1 Incyte Corporation $130.00 07/17/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690575
Principal investigator 1 Incyte Corporation $130.00 07/17/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690577
Principal investigator 1 Incyte Corporation $80.00 07/17/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690829
Principal investigator 1 Incyte Corporation $17,090.00 07/17/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690833
Principal investigator 1 Incyte Corporation $5,081.66 07/11/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
An Open-Label, Single-Arm, Phase 4 Study of Ruxolitinib Cream in Adults With Atopic Dermatitis Experiencing Sleep Disturbance in the United States (MORPHEUS) No dispute reported 06/30/2026 1134690787
Principal investigator 1 Incyte Corporation $2,066.19 07/11/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) No dispute reported 06/30/2026 1134690789
Principal investigator 1 Incyte Corporation $3,604.90 07/11/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
An Open-Label, Single-Arm, Phase 4 Study of Ruxolitinib Cream in Adults With Atopic Dermatitis Experiencing Sleep Disturbance in the United States (MORPHEUS) No dispute reported 06/30/2026 1134690803
Principal investigator 1 Incyte Corporation $1,364.00 07/10/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690939
Principal investigator 1 Incyte Corporation $82.20 07/02/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690427
Principal investigator 1 Incyte Corporation $82.20 07/02/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690473
Principal investigator 1 Incyte Corporation $82.20 07/02/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690475
Principal investigator 1 Incyte Corporation $82.20 07/02/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690477
Principal investigator 1 Incyte Corporation $24.66 07/02/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690531
Principal investigator 1 Incyte Corporation $24.66 07/02/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690533
Principal investigator 1 Incyte Corporation $24.66 07/02/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690535
Principal investigator 1 Incyte Corporation $24.66 07/02/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690537
Principal investigator 1 Incyte Corporation $45.80 07/02/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690807
Principal investigator 1 Incyte Corporation $19.57 07/02/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690809
Principal investigator 1 Incyte Corporation $1.06 07/02/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690811
Principal investigator 1 Incyte Corporation $21.63 07/02/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690813
Principal investigator 1 Incyte Corporation $4.24 07/02/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690815
Principal investigator 1 Incyte Corporation $16.18 07/02/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690817
Principal investigator 1 Incyte Corporation $114.50 07/02/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690819
Principal investigator 1 Incyte Corporation $17.01 07/02/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690843
Principal investigator 1 Incyte Corporation $21.20 07/02/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690909
Principal investigator 1 Incyte Corporation $2,640.47 06/27/2024 Non-covered Recipient Entity
PRINCIPLE RESEARCH SOLUTIONS
A Safety and Efficacy Study of Ruxolitinib Cream Combined With Narrow-Band Ultraviolet B Phototherapy in Participants With Vitiligo No dispute reported 06/30/2026 1134709985
Principal investigator 1 Incyte Corporation $1,942.00 06/14/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690401
Principal investigator 1 Incyte Corporation $1,942.00 06/14/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690409
Principal investigator 1 Incyte Corporation $1,942.00 06/14/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690411
Principal investigator 1 Incyte Corporation $1,942.00 06/14/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690413
Principal investigator 1 Incyte Corporation $1,334.00 06/14/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690415
Principal investigator 1 Incyte Corporation $1,334.00 06/14/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690547
Principal investigator 1 Incyte Corporation $1,334.00 06/14/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690549
Principal investigator 1 Incyte Corporation $1,334.00 06/14/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690551
Principal investigator 1 Incyte Corporation $1,334.00 06/14/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690553
Principal investigator 1 Incyte Corporation $1,942.00 06/14/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690567
Principal investigator 1 Incyte Corporation $1,364.00 06/14/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690751
Principal investigator 1 Incyte Corporation $162.24 06/13/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
An Open-Label, Single-Arm, Phase 4 Study of Ruxolitinib Cream in Adults With Atopic Dermatitis Experiencing Sleep Disturbance in the United States (MORPHEUS) No dispute reported 06/30/2026 1134690781
Principal investigator 1 Incyte Corporation $105.29 06/06/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
An Open-Label, Single-Arm, Phase 4 Study of Ruxolitinib Cream in Adults With Atopic Dermatitis Experiencing Sleep Disturbance in the United States (MORPHEUS) No dispute reported 06/30/2026 1134690779
Principal investigator 1 Incyte Corporation $670.00 06/05/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690617
Principal investigator 1 Incyte Corporation $750.00 06/05/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690921
Principal investigator 1 Incyte Corporation $62.27 06/04/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690391
Principal investigator 1 Incyte Corporation $62.27 06/04/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690405
Principal investigator 1 Incyte Corporation $62.27 06/04/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690425
Principal investigator 1 Incyte Corporation $4,638.65 06/04/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
An Open-Label, Single-Arm, Phase 4 Study of Ruxolitinib Cream in Adults With Atopic Dermatitis Experiencing Sleep Disturbance in the United States (MORPHEUS) No dispute reported 06/30/2026 1134690799
Principal investigator 1 Incyte Corporation $8,932.57 06/04/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
An Open-Label, Single-Arm, Phase 4 Study of Ruxolitinib Cream in Adults With Atopic Dermatitis Experiencing Sleep Disturbance in the United States (MORPHEUS) No dispute reported 06/30/2026 1134690905
Principal investigator 1 Incyte Corporation $59.13 06/04/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690933
Principal investigator 1 Incyte Corporation $1,030.00 06/04/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 1134690949
Principal investigator 1 Incyte Corporation $220.00 05/23/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
An Open-Label, Single-Arm, Phase 4 Study of Ruxolitinib Cream in Adults With Atopic Dermatitis Experiencing Sleep Disturbance in the United States (MORPHEUS) No dispute reported 06/30/2026 1134690783
Principal investigator 1 Incyte Corporation $117.29 05/23/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
An Open-Label, Single-Arm, Phase 4 Study of Ruxolitinib Cream in Adults With Atopic Dermatitis Experiencing Sleep Disturbance in the United States (MORPHEUS) No dispute reported 06/30/2026 1134690925
Principal investigator 1 Incyte Corporation $300.00 05/16/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) No dispute reported 06/30/2026 1134690785
Principal investigator 1 Incyte Corporation $575.04 05/16/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
An Open-Label, Single-Arm, Phase 4 Study of Ruxolitinib Cream in Adults With Atopic Dermatitis Experiencing Sleep Disturbance in the United States (MORPHEUS) No dispute reported 06/30/2026 1134690967
Principal investigator 1 Incyte Corporation $336.00 05/15/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690747
Principal investigator 1 Incyte Corporation $360.00 05/15/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690749
Principal investigator 1 Incyte Corporation $150.00 05/15/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690963
Principal investigator 1 Incyte Corporation $54.76 05/06/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690729
Principal investigator 1 Incyte Corporation $74.04 05/06/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690731
Principal investigator 1 Incyte Corporation $113.26 05/06/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690733
Principal investigator 1 Incyte Corporation $103.05 05/06/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690935
Principal investigator 1 Incyte Corporation $1,334.00 05/03/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690395
Principal investigator 1 Incyte Corporation $1,334.00 05/03/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690407
Principal investigator 1 Incyte Corporation $1,334.00 05/03/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690557
Principal investigator 1 Incyte Corporation $1,334.00 05/03/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690559
Principal investigator 1 Incyte Corporation $1,334.00 05/03/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690561
Principal investigator 1 Incyte Corporation $1,334.00 05/03/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690563
Principal investigator 1 Incyte Corporation $1,334.00 05/03/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690565
Principal investigator 1 Incyte Corporation $1,942.00 05/03/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690941
Principal investigator 1 Incyte Corporation $177.39 05/02/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690627
Principal investigator 1 Incyte Corporation $186.81 05/02/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690771
Principal investigator 1 Incyte Corporation $80.15 05/02/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690913
Principal investigator 1 Incyte Corporation $1,000.00 05/01/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690393
Principal investigator 1 Incyte Corporation $1,000.00 05/01/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690545
Principal investigator 1 Incyte Corporation $5,000.00 05/01/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690735
Principal investigator 1 Incyte Corporation $500.00 05/01/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690929
Principal investigator 1 Incyte Corporation $1,306.64 05/01/2024 Non-covered Recipient Entity
PRINCIPLE RESEARCH SOLUTIONS
A Safety and Efficacy Study of Ruxolitinib Cream Combined With Narrow-Band Ultraviolet B Phototherapy in Participants With Vitiligo No dispute reported 06/30/2026 1134709987
Principal investigator 1 Boehringer Ingelheim International GmbH $819.50 04/25/2024 Non-covered Recipient Entity
Dermatology Specialists Of Spokane
Speso moderate to severe HS Phase IIb/III No dispute reported 06/30/2026 1101074123
Principal investigator 1 Incyte Corporation $1,472.70 04/25/2024 Non-covered Recipient Entity
PRINCIPLE RESEARCH SOLUTIONS
A Safety and Efficacy Study of Ruxolitinib Cream Combined With Narrow-Band Ultraviolet B Phototherapy in Participants With Vitiligo No dispute reported 06/30/2026 1134709983
Principal investigator 1 Incyte Corporation $840.00 04/12/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690739
Principal investigator 1 Incyte Corporation $800.00 04/12/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690741
Principal investigator 1 Incyte Corporation $1,070.00 04/12/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690743
Principal investigator 1 Incyte Corporation $1,134.00 04/12/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690745
Principal investigator 1 Incyte Corporation $11,927.52 04/10/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
An Open-Label, Single-Arm, Phase 4 Study of Ruxolitinib Cream in Adults With Atopic Dermatitis Experiencing Sleep Disturbance in the United States (MORPHEUS) No dispute reported 06/30/2026 1134690937
Principal investigator 1 Incyte Corporation $1,334.00 04/08/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690397
Principal investigator 1 Incyte Corporation $1,334.00 04/08/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690539
Principal investigator 1 Incyte Corporation $1,334.00 04/08/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690541
Principal investigator 1 Incyte Corporation $1,334.00 04/08/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690543
Principal investigator 1 Incyte Corporation $1,942.00 04/08/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690737
Principal investigator 1 Incyte Corporation $32.28 04/02/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690307
Principal investigator 1 Incyte Corporation $53.80 04/02/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690309
Principal investigator 1 Incyte Corporation $238.50 04/02/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690399
Principal investigator 1 Incyte Corporation $106.00 04/02/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690403
Principal investigator 1 Incyte Corporation $238.50 04/02/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690417
Principal investigator 1 Incyte Corporation $106.00 04/02/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690419
Principal investigator 1 Incyte Corporation $32.28 04/02/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690421
Principal investigator 1 Incyte Corporation $106.00 04/02/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690423
Principal investigator 1 Incyte Corporation $53.80 04/02/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690511
Principal investigator 1 Incyte Corporation $53.80 04/02/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690513
Principal investigator 1 Incyte Corporation $43.04 04/02/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690623
Principal investigator 1 Incyte Corporation $21.52 04/02/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690625
Principal investigator 1 Incyte Corporation $63.60 04/02/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690753
Principal investigator 1 Incyte Corporation $137.80 04/02/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690755
Principal investigator 1 Incyte Corporation $68.90 04/02/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690757
Principal investigator 1 Incyte Corporation $206.70 04/02/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690759
Principal investigator 1 Incyte Corporation $148.40 04/02/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690761
Principal investigator 1 Incyte Corporation $127.20 04/02/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690763
Principal investigator 1 Incyte Corporation $57.25 04/02/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690765
Principal investigator 1 Incyte Corporation $15.50 04/02/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690767
Principal investigator 1 Incyte Corporation $58.30 04/02/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690769
Principal investigator 1 Incyte Corporation $74.04 04/02/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690773
Principal investigator 1 Incyte Corporation $0.93 04/02/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690775
Principal investigator 1 Incyte Corporation $64.72 04/02/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690777
Principal investigator 1 Incyte Corporation $74.20 04/02/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690915
Principal investigator 1 Incyte Corporation $37.66 04/02/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690919
Principal investigator 1 Incyte Corporation $21.20 04/02/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690931
Principal investigator 1 Incyte Corporation $900.00 03/20/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690709
Principal investigator 1 Incyte Corporation $1,000.00 03/20/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690711
Principal investigator 1 Incyte Corporation $600.00 03/20/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690725
Principal investigator 1 Incyte Corporation $1,231.00 03/20/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690727
Principal investigator 1 Incyte Corporation $125.00 03/20/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690923
Principal investigator 1 Kiniksa Pharmaceuticals International, plc $23,186.03 03/18/2024 Non-covered Recipient Entity
Dermatology Specialist of Spokane
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 1154868922
Principal investigator 1 Incyte Corporation $1,334.00 03/11/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690311
Principal investigator 1 Incyte Corporation $1,334.00 03/11/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690341
Principal investigator 1 Incyte Corporation $1,334.00 03/11/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690357
Principal investigator 1 Incyte Corporation $1,334.00 03/11/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690367
Principal investigator 1 Incyte Corporation $1,334.00 03/11/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690383
Principal investigator 1 Incyte Corporation $1,334.00 03/11/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690387
Principal investigator 1 Incyte Corporation $1,334.00 03/11/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690597
Principal investigator 1 Incyte Corporation $1,334.00 03/11/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690599
Principal investigator 1 Incyte Corporation $1,334.00 03/11/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690601
Principal investigator 1 Incyte Corporation $1,473.00 03/11/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690719
Principal investigator 1 Incyte Corporation $1,942.00 03/11/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690721
Principal investigator 1 Incyte Corporation $450.00 03/07/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
An Open-Label, Single-Arm, Phase 4 Study of Ruxolitinib Cream in Adults With Atopic Dermatitis Experiencing Sleep Disturbance in the United States (MORPHEUS) No dispute reported 06/30/2026 1134690663
Principal investigator 1 Incyte Corporation $1,056.38 03/06/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) No dispute reported 06/30/2026 1134690651
Principal investigator 1 Incyte Corporation $1,300.50 03/06/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
An Open-Label, Single-Arm, Phase 4 Study of Ruxolitinib Cream in Adults With Atopic Dermatitis Experiencing Sleep Disturbance in the United States (MORPHEUS) No dispute reported 06/30/2026 1134690661
Principal investigator 1 Incyte Corporation $1,231.00 03/06/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690723
Principal investigator 1 Incyte Corporation $2,710.50 03/06/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
An Open-Label, Single-Arm, Phase 4 Study of Ruxolitinib Cream in Adults With Atopic Dermatitis Experiencing Sleep Disturbance in the United States (MORPHEUS) No dispute reported 06/30/2026 1134690947
Principal investigator 1 Incyte Corporation $24.66 03/04/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690327
Principal investigator 1 Incyte Corporation $24.66 03/04/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690347
Principal investigator 1 Incyte Corporation $24.66 03/04/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690571
Principal investigator 1 Incyte Corporation $24.66 03/04/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690573
Principal investigator 1 Incyte Corporation $59.13 03/04/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690665
Principal investigator 1 Incyte Corporation $135.40 03/04/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690671
Principal investigator 1 Incyte Corporation $7.29 03/04/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690685
Principal investigator 1 Incyte Corporation $74.04 03/04/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690693
Principal investigator 1 Incyte Corporation $124.54 03/04/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690911
Principal investigator 1 Incyte Corporation $43.74 03/04/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690943
Principal investigator 1 Incyte Corporation $828.00 02/22/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
An Open-Label, Single-Arm, Phase 4 Study of Ruxolitinib Cream in Adults With Atopic Dermatitis Experiencing Sleep Disturbance in the United States (MORPHEUS) No dispute reported 06/30/2026 1134690659
Principal investigator 1 Incyte Corporation $58.00 02/15/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
An Open-Label, Single-Arm, Phase 4 Study of Ruxolitinib Cream in Adults With Atopic Dermatitis Experiencing Sleep Disturbance in the United States (MORPHEUS) No dispute reported 06/30/2026 1134690653
Principal investigator 1 Amgen Inc. $7,667.50 02/05/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE PLLC
P2A DAX in Moderate-to-Severe AA No dispute reported 06/30/2026 1096312215
Principal investigator 1 Incyte Corporation $1,334.00 02/05/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690335
Principal investigator 1 Incyte Corporation $1,473.00 02/05/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690343
Principal investigator 1 Incyte Corporation $1,473.00 02/05/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690361
Principal investigator 1 Incyte Corporation $1,334.00 02/05/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690369
Principal investigator 1 Incyte Corporation $1,334.00 02/05/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690521
Principal investigator 1 Incyte Corporation $1,334.00 02/05/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690523
Principal investigator 1 Incyte Corporation $1,334.00 02/05/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690525
Principal investigator 1 Incyte Corporation $1,422.00 02/05/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690715
Principal investigator 1 Eli Lilly and Company $371,409.34 02/02/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A PHASE 2B, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE ELTREKIBART IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA No dispute reported 06/30/2026 1137358621
Principal investigator 1 Incyte Corporation $8.22 02/02/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690315
Principal investigator 1 Incyte Corporation $54.76 02/02/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690317
Principal investigator 1 Incyte Corporation $24.68 02/02/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690333
Principal investigator 1 Incyte Corporation $54.76 02/02/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690365
Principal investigator 1 Incyte Corporation $8.22 02/02/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690375
Principal investigator 1 Incyte Corporation $8.22 02/02/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690377
Principal investigator 1 Incyte Corporation $24.68 02/02/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690381
Principal investigator 1 Incyte Corporation $41.10 02/02/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690479
Principal investigator 1 Incyte Corporation $41.10 02/02/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690481
Principal investigator 1 Incyte Corporation $41.10 02/02/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690483
Principal investigator 1 Incyte Corporation $41.10 02/02/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690485
Principal investigator 1 Incyte Corporation $8.22 02/02/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690587
Principal investigator 1 Incyte Corporation $62.27 02/02/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690667
Principal investigator 1 Incyte Corporation $64.72 02/02/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690669
Principal investigator 1 Incyte Corporation $8.24 02/02/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690673
Principal investigator 1 Incyte Corporation $11.45 02/02/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690675
Principal investigator 1 Incyte Corporation $1.86 02/02/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690683
Principal investigator 1 Incyte Corporation $194.65 02/02/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690697
Principal investigator 1 Incyte Corporation $57.25 02/02/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690699
Principal investigator 1 Incyte Corporation $4.12 02/02/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690701
Principal investigator 1 Incyte Corporation $3.18 02/02/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690703
Principal investigator 1 Incyte Corporation $194.16 02/02/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690953
Principal investigator 1 Incyte Corporation $11.66 02/02/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690965
Principal investigator 1 Incyte Corporation $3,588.95 02/01/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
An Open-Label, Single-Arm, Phase 4 Study of Ruxolitinib Cream in Adults With Atopic Dermatitis Experiencing Sleep Disturbance in the United States (MORPHEUS) No dispute reported 06/30/2026 1134690655
Principal investigator 1 Incyte Corporation $2,007.68 02/01/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
An Open-Label, Single-Arm, Phase 4 Study of Ruxolitinib Cream in Adults With Atopic Dermatitis Experiencing Sleep Disturbance in the United States (MORPHEUS) No dispute reported 06/30/2026 1134690657
Principal investigator 1 Incyte Corporation $2,803.94 01/26/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) No dispute reported 06/30/2026 1134690961
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $43,184.11 01/19/2024 Non-covered Recipient Entity
Dermatology Specialists Of Spokane
A Phase 2b, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled 54-Week Study to Evaluate the Efficacy and Safety of Rezpegaldesleukin in the Treatment of Adult Patients with Moderate-to-Severe Atopic Dermatitis No dispute reported 06/30/2026 1123476974
Principal investigator 1 Incyte Corporation $430.00 01/12/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
An Open-Label, Single-Arm, Phase 4 Study of Ruxolitinib Cream in Adults With Atopic Dermatitis Experiencing Sleep Disturbance in the United States (MORPHEUS) No dispute reported 06/30/2026 1134690647
Principal investigator 1 Incyte Corporation $450.00 01/12/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages 2 Years to 12 Years) With Atopic Dermatitis (TRuE-AD3) No dispute reported 06/30/2026 1134690957
Principal investigator 1 Incyte Corporation $1,422.00 01/10/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690337
Principal investigator 1 Incyte Corporation $1,334.00 01/10/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690339
Principal investigator 1 Incyte Corporation $1,422.00 01/10/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690363
Principal investigator 1 Incyte Corporation $1,334.00 01/10/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690385
Principal investigator 1 Incyte Corporation $1,334.00 01/10/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690389
Principal investigator 1 Incyte Corporation $1,473.00 01/10/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690487
Principal investigator 1 Incyte Corporation $1,473.00 01/10/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690489
Principal investigator 1 Incyte Corporation $1,334.00 01/10/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690579
Principal investigator 1 Incyte Corporation $1,334.00 01/10/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690581
Principal investigator 1 Incyte Corporation $1,334.00 01/10/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690583
Principal investigator 1 Incyte Corporation $1,334.00 01/10/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690585
Principal investigator 1 Incyte Corporation $2,128.00 01/10/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690713
Principal investigator 1 Incyte Corporation $1,461.00 01/10/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690717
Principal investigator 1 Incyte Corporation $111.28 01/08/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
An Open-Label, Single-Arm, Phase 4 Study of Ruxolitinib Cream in Adults With Atopic Dermatitis Experiencing Sleep Disturbance in the United States (MORPHEUS) No dispute reported 06/30/2026 1134690649
Principal investigator 1 Incyte Corporation $16.18 01/04/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690303
Principal investigator 1 Incyte Corporation $82.20 01/04/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690305
Principal investigator 1 Incyte Corporation $82.20 01/04/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690319
Principal investigator 1 Incyte Corporation $118.26 01/04/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690321
Principal investigator 1 Incyte Corporation $3.10 01/04/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690323
Principal investigator 1 Incyte Corporation $9.72 01/04/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690325
Principal investigator 1 Incyte Corporation $24.30 01/04/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690329
Principal investigator 1 Incyte Corporation $16.18 01/04/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690331
Principal investigator 1 Incyte Corporation $82.20 01/04/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690345
Principal investigator 1 Incyte Corporation $3.10 01/04/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690349
Principal investigator 1 Incyte Corporation $24.30 01/04/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690351
Principal investigator 1 Incyte Corporation $3.10 01/04/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690353
Principal investigator 1 Incyte Corporation $82.20 01/04/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690355
Principal investigator 1 Incyte Corporation $82.20 01/04/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690359
Principal investigator 1 Incyte Corporation $246.80 01/04/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690371
Principal investigator 1 Incyte Corporation $82.20 01/04/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690373
Principal investigator 1 Incyte Corporation $246.80 01/04/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690379
Principal investigator 1 Incyte Corporation $2.43 01/04/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690503
Principal investigator 1 Incyte Corporation $2.43 01/04/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690505
Principal investigator 1 Incyte Corporation $118.26 01/04/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690507
Principal investigator 1 Incyte Corporation $118.26 01/04/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690509
Principal investigator 1 Incyte Corporation $9.72 01/04/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690555
Principal investigator 1 Incyte Corporation $24.30 01/04/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690589
Principal investigator 1 Incyte Corporation $24.30 01/04/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690591
Principal investigator 1 Incyte Corporation $16.18 01/04/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690593
Principal investigator 1 Incyte Corporation $246.80 01/04/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690595
Principal investigator 1 Incyte Corporation $82.20 01/04/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690603
Principal investigator 1 Incyte Corporation $82.20 01/04/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690605
Principal investigator 1 Incyte Corporation $82.20 01/04/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690607
Principal investigator 1 Incyte Corporation $82.20 01/04/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690609
Principal investigator 1 Incyte Corporation $82.20 01/04/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690611
Principal investigator 1 Incyte Corporation $82.20 01/04/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690613
Principal investigator 1 Incyte Corporation $0.62 01/04/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690677
Principal investigator 1 Incyte Corporation $0.93 01/04/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690679
Principal investigator 1 Incyte Corporation $62.27 01/04/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690681
Principal investigator 1 Incyte Corporation $103.05 01/04/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690687
Principal investigator 1 Incyte Corporation $91.60 01/04/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690689
Principal investigator 1 Incyte Corporation $22.90 01/04/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690691
Principal investigator 1 Incyte Corporation $160.30 01/04/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690695
Principal investigator 1 Incyte Corporation $373.62 01/04/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690705
Principal investigator 1 Incyte Corporation $498.16 01/04/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690707
Principal investigator 1 Incyte Corporation $0.31 01/04/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690901
Principal investigator 1 Incyte Corporation $148.85 01/04/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1134690945
Principal investigator 1 Amgen Inc. $9,362.73 01/03/2024 Non-covered Recipient Entity
DERMATOLOGY SPECIALISTS OF SPOKANE
P2A DAX in Moderate-to-Severe AA No dispute reported 06/30/2026 1096306725
Principal investigator 1 Kiniksa Pharmaceuticals International, plc $3,750.00 01/03/2024 Non-covered Recipient Entity
Dermatology Specialist of Spokane
A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis No dispute reported 06/30/2026 1154868918